Prediction Model for Postoperative Headache After Transsphenoidal Pituitary Surgery

NCT07446036 · tracked via the Priya Life Science China tracker

Sponsor

Beijing Tiantan Hospital

Phase

Observational

Started

2026-01-01

Last updated

2026-03-03

Condition(s) studied

HeadachePituitary AdenomaEndonasal SurgeryPredictive Model

Investigational drug(s) / intervention(s)

Transsphenoidal Pituitary Surgery

Transsphenoidal Pituitary Surgery: all pituitary cases recruited in the study received transsphenoidal pituitary surgery

Study summary

Primary Objective: This observational study aims to construct a predictive model for short-term headache following endonasal pituitary adenoma surgery and to identify risk factors associated with postoperative headache after endonasal surgery.

Secondary Objectives: First, to investigate the relationship between the severity of short-term postoperative headache and long-term life burden (at 1 and 3 months postoperatively), as well as its correlation with quality of life. Second, to elucidate the clinical characteristics and evolutionary patterns of short-term postoperative headache. Third, to explore key aspects of perioperative management, including changes in nasal cavity status and postoperative mobilization, which may optimize the management of short-term postoperative headache.

Primary outcome measure1: VAS scale（0-10） Primary outcome measure2: feature of postoperative headache including (location, type, length, accompany symptom, and factors that elevate or sharpen headache, analgesics usage, analgesics frequency, analgesics effect) Secondary outcome measure 1: HIT-6 test Secondary outcome measure 2: Postoperative Olfaction Secondary outcome measure 3: Postoperative Massive Epistaxis

Participants will undergo daily assessments postoperatively, which include evaluations of headache, nasal cavity status, and analgesic drug usage. These assessments will continue until two consecutive Visual Analog Scale (VAS) scores are less than 4. Additionally, participants will complete questionnaires, including the Headache Impact (HIT-6) test at 4 weeks and 12 weeks postoperatively.

Eligibility

Sex

ALL

Min age

18 Years

Max age

100 Years

Healthy volunteers

Inclusion Criteria: 1. Age ≥ 18 years old. 2. Preoperatively diagnosed with pituitary adenoma by clinical and radiological (MRI) evaluation, and scheduled to undergo primary or recurrent neuroendoscopic transsphenoidal surgery in the Tumor Ward 7 of the Department of Neurosurgery at Beijing Tiantan Hospital. 3. Fully conscious with adequate cognitive and comprehension abilities to complete pain assessment scales (VAS) and questionnaires (HIT-6, psychological scales, etc.). 4. Willing to participate in this study and provide written informed consent. Exclusion Criteria: 1. Presence of other intracranial tumors, or undergoing transsphenoidal surgery due to other diseases (such as aneurysms, Rathke's cysts, meningiomas, etc.). 2. History of chronic headache (such as migraines, tension headaches) with a frequency of \>4 times per month, or long-term dependence on analgesic medications. 3. Presence of severe nasal or sinus diseases preoperatively (such as chronic sinusitis requiring surgical intervention, nasal polyps) or a history of nasal surgery within the recent 3 months. 4. History of severe psychiatric or psychological disorders, or presence of cognitive impairment or language communication barriers that prevent participation in study assessments. 5. Pregnant or breastfeeding women. 6. Conversion to craniotomy during surgery due to various reasons (such as uncontrollable bleeding, change in tumor nature).

Primary outcome measure(s)

Visual Analogue Scale (VAS) — Postoperative assessments shall be performed daily from Day 1, continuing until two consecutive VAS scores below 4 are obtained or until two weeks postoperatively, whichever occurs first.
The Visual Analogue Scale (VAS) is scored from 0 to 10, with higher scores denoting greater headache severity. Postoperative short-term headache is defined as the occurrence of two consecutive peak VAS scores ≥4 within the two-week postoperative period.

Trial sites (1)

Facility	City	Region	Status
Beijing Tiantan Hospital	Beijing	Fengtai

More Beijing Tiantan Hospital trials in China

Safety and Efficacy Study of Anti-B7-H3 CAR-T Cell Therapy for Recurrent Glioblastoma Active, not recruiting

Stent Implantation Versus Medical Therapy for Idiopathic IntracraniaL Hypertension (SIMPLE) Recruiting

Shuxuening Injection in the Treatment With Intravenous Thrombolysis in Patients With Ischemic Stroke (SHINY) Recruiting

Risk Prediction Model for Cerebrovascular Events in Carotid Artery Stenosis Enrolling by invitation

The Efficacy and Safety of Pregabalin and Crisugabalin in Patients With Fibromyalgia Recruiting

Other trials for the same condition

Headache Registration and Followup Initiated by Tongji Hospital, HUST Recruiting

Efficacy and Safety of Transcutaneous Auricular Vagus Nerve Stimulation for Postoperative Headache Following Stent-Assisted Coiling of Unruptured Intracranial Aneurysms Recruiting

Predictive Value of Serum and Tissue Molecular Markers and Imaging Features in the Invasiveness and Prognosis of Pituitary Neuroendocrine Tumors Recruiting

Hydrocortisone in Hormone Replacement Therapy for Large Pituitary Neuroendocrine Tumors Recruiting

Clinical Trial of an Anti-Fog Drainage Device for Endoscopic Endonasal Sellar Region Tumor Surgery Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07446036 on ClinicalTrials.gov ↗ ← All trials in China